Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

NCT05388487 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: HF1K16 /Arm 45 mg/m²
DRUG: HF1K16 /Arm 90 mg/m²
DRUG: HF1K16 /Arm 120 mg/m²
DRUG: HF1K16 /Arm 160 mg/m²
DRUG: HF1K16 /Arm 120 mg or 180 mg

Sponsor

HighField Biopharmaceuticals Corporation

Collaborators

[object Object]